Sacubitril/valsartan in heart failure and end‐stage renal insufficiency. (30th October 2019)

• Record Type: Journal Article
• Authors: Heyse, Alex; Manhaeghe, Lynn; Mahieu, Elien; Vanfraechem, Céline; Van Durme, Frederik
• Is Part Of: ESC heart failure. Volume 6:Number 6(2019)
• Page Start: 1331
• Page End: 1333
• Publication Date: 2019-10-30
• Subjects: Sacubitril/valsartan -- ARNI -- Heart failure -- Dialysis -- Chronic kidney disease; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.12544
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: The aim of this report is to describe the feasibility and tolerability of medical treatment with sacubitril/valsartan in a patient treated with hemodialysis. We describe the case of a 67‐year‐old man with heart failure with reduced ejection fraction due to an ischemic cardiomyopathy and renal insufficiency undergoing hemodialysis. Because of worsening heart failure with no other therapeutic options, a treatment with sacubitril/valsartan was started. Although this patient had a very low systolic blood pressure, he could tolerate a moderate dose of 49/51 mg twice daily. After initiation of sacubitril/valsartan, there was a symptomatic improvement with a clear reduction NT‐proBNP, accompanied by a decrease in filling pressures. In conclusion, in this patient with severe heart failure undergoing hemodialysis, treatment with sacubitril/valsartan was feasible, safe, and improved heart failure symptoms.